Sugi Predict

Sugi Predict / Compounds / SCHEMBL3537593

SCHEMBL3537593

SCHEMBL3537593

COC(=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.57
▸ CA1 P00915 2/20 0.57
▸ CA2 P00918 2/20 0.57
▸ CA7 P43166 2/20 0.57
▸ CA9 Q16790 2/20 0.57
▸ CA14 Q9ULX7 2/20 0.57
▸ PDK2 Q15119 1/20 0.57
▸ PDK4 Q16654 1/20 0.57
▸ GAA P10253 1/20 0.50
▸ LMNA P02545 3/20 0.47
▸ TSHR P16473 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ EGFR P00533 2/20 0.46
▸ HSD11B1 P28845 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ MYC P01106 1/20 0.44
▸ HPGD P15428 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPK1 P28482 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569165 0.88 HSD11B1 (0.47) CA12CA1CA2CA7CA9
SCHEMBL18763951 0.86 HSD11B1 (0.50) CA12CA1CA2CA7CA9
SCHEMBL3901811 0.85 HSD11B1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL974920 0.85 HSD11B1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL3901554 0.84 CFTR (0.44) CA12CA1CA2CA7CA9
SCHEMBL3187945 0.84 KMT2A (0.45) GAALMNASMN1; SMN2HSD11B1NPC1
SCHEMBL12470804 0.82 CXCR2 (0.46) CA12CA1CA2CA7CA9
SCHEMBL13648785 0.82 NPC1 (0.50) LMNATSHRSMN1; SMN2HSD11B1NPC1
SCHEMBL3904794 0.82 HSD11B1 (0.43) CA12CA1CA2CA7CA9
SCHEMBL24436789 0.81 CA12 (0.64) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289781-A1 TRIFLUOROMETHANESULFONYLATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANESULFONYL COMPOUND CENTRAL GLASS COMPANY, LIMITED (JP) 2025-09-18 — — US disclosed
WO-2023214552-A1 TRIFLUOROMETHANE SULFONYLATION AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANE SULFONYL COMPOUND セントラル硝子株式会社 2023-11-09 — — WO disclosed
US-9370519-B2 Macrocyclic FLT3 kinase inhibitors ONCODESIGN S.A. (FR) 2016-06-21 — — US disclosed
US-9370519-B2 Macrocyclic FLT3 kinase inhibitors ONCODESIGN S.A. (FR) 2016-06-21 — — US disclosed
US-20150283141-A1 MACROCYCLIC FLT3 KINASE INHIBITORS ONCODESIGN SA (FR) 2015-10-08 — — US disclosed
US-20150283141-A1 MACROCYCLIC FLT3 KINASE INHIBITORS ONCODESIGN SA (FR) 2015-10-08 — — US disclosed
US-9090630-B2 Macrocyclic FLT3 kinase inhibitors ONCODESIGN S.A. (FR) 2015-07-28 — — US disclosed
US-9090630-B2 Macrocyclic FLT3 kinase inhibitors ONCODESIGN S.A. (FR) 2015-07-28 — — US disclosed
US-20140303159-A1 MACROCYCLIC FLT3 KINASE INHIBITORS ONCODESIGN S.A. (FR) 2014-10-09 — — US disclosed
US-20140303159-A1 MACROCYCLIC FLT3 KINASE INHIBITORS ONCODESIGN S.A. (FR) 2014-10-09 — — US disclosed
US-20110021771-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2011-01-27 — — US disclosed
US-7674823-B2 DNA-PK inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-03-09 — — US disclosed
EP-1417196-B1 DNA-PK INHIBITORS CANCER REC TECH LTD (GB) 2008-10-22 — — EP disclosed
US-20070238729-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-10-11 — — US disclosed
US-7226918-B2 DNA-PK inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-06-05 — — US disclosed
US-20040192687-A1 Dna-pk inhibitors CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2004-09-30 — — US disclosed
EP-1417196-A1 DNA-PK INHIBITORS Cancer Research Technology Limited (GB) 2004-05-12 — — EP disclosed
WO-2003024949-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-03-27 — — WO disclosed
EP-0620815-A1 PHENOL DERIVATIVES AS AGONISTS OF A CYCLIC AMP DEPENDENT PROTEIN KINASE SMITHKLINE BEECHAM PLC (GB) 1994-10-26 — — EP disclosed
WO-1993010107-A1 PHENOL DERIVATIVES AS AGONISTS OF A CYCLIC AMP DEPENDENT PROTEIN KINASE SMITHKLINE BEECHAM PLC (GB) 1993-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021771-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC3 CA12 1467/4885CA1 409/4885CA2 720/4885
US-20250289781-A1 TRIFLUOROMETHANESULFONYLATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANESULFONYL COMPOUND AFF1, BRAF, AFF2 CA12 718/4885CA1 542/4885CA2 2177/4885
US-20040192687-A1 Dna-pk inhibitors ATM, CHEK1, XRCC6 CA12 4636/4885CA1 3884/4885CA2 2840/4885
US-20140303159-A1 MACROCYCLIC FLT3 KINASE INHIBITORS FLT3, ABL1, FER CA12 4601/4885CA1 4056/4885CA2 3897/4885
US-20070238729-A1 DNA-PK INHIBITORS ATM, CHEK2, CHEK1 CA12 4438/4885CA1 3876/4885CA2 3037/4885
US-20150283141-A1 MACROCYCLIC FLT3 KINASE INHIBITORS FLT3, ABL1, FER CA12 4601/4885CA1 4056/4885CA2 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.